1502 related articles for article (PubMed ID: 25124078)
1. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
2. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
[TBL] [Abstract][Full Text] [Related]
3. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.
van Lelyveld SF; Gras L; Kesselring A; Zhang S; De Wolf F; Wensing AM; Hoepelman AI;
AIDS; 2012 Feb; 26(4):465-74. PubMed ID: 22112603
[TBL] [Abstract][Full Text] [Related]
4. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
[TBL] [Abstract][Full Text] [Related]
5. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice.
Vallecillo G; Domingo P; Mallolas J; Blanch J; Ferrer E; Cervantes M; Pedrol E; Knobel H; Llibre JM
AIDS Res Hum Retroviruses; 2012 Feb; 28(2):165-70. PubMed ID: 21790273
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
[TBL] [Abstract][Full Text] [Related]
9. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in Uganda.
Castelnuovo B; Kiragga A; Musaazi J; Sempa J; Mubiru F; Wanyama J; Wandera B; Kamya MR; Kambugu A
PLoS One; 2015; 10(12):e0142722. PubMed ID: 26642214
[TBL] [Abstract][Full Text] [Related]
11. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.
Fatti G; Shaikh N; Eley B; Grimwood A
AIDS Care; 2014 Apr; 26(4):448-53. PubMed ID: 24215157
[TBL] [Abstract][Full Text] [Related]
12. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
[TBL] [Abstract][Full Text] [Related]
13. Expansion of HIV-1 screening and anti-retroviral treatment programs in a resource-poor setting: results from a faith-based organization in Jos, Plateau State, Nigeria.
Lum H; Isichei C; Isichei-Wakili M; Redfield R
Afr Health Sci; 2007 Jun; 7(2):93-100. PubMed ID: 17594286
[TBL] [Abstract][Full Text] [Related]
14. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of baseline CD4(+) cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting.
Mills EJ; Bakanda C; Birungi J; Yaya S; Ford N;
AIDS; 2012 Jul; 26(11):1425-9. PubMed ID: 22526520
[TBL] [Abstract][Full Text] [Related]
16. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
17. Effect of a clinical decision support system on early action on immunological treatment failure in patients with HIV in Kenya: a cluster randomised controlled trial.
Oluoch T; Katana A; Kwaro D; Santas X; Langat P; Mwalili S; Muthusi K; Okeyo N; Ojwang JK; Cornet R; Abu-Hanna A; de Keizer N
Lancet HIV; 2016 Feb; 3(2):e76-84. PubMed ID: 26847229
[TBL] [Abstract][Full Text] [Related]
18. HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia.
Boettiger DC; Khol V; Durier N; Law M; Sun LP
Antivir Ther; 2016; 21(8):725-730. PubMed ID: 27124891
[TBL] [Abstract][Full Text] [Related]
19. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
[TBL] [Abstract][Full Text] [Related]
20. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
